Mirati Spies ‘First-In-Class’ Chance For KRAS Inhibitor In Pancreatic Cancer
Adds To Colorectal Cancer Opportunity
Executive Summary
While chasing Amgen’s Lumakras in NSCLC, Mirati looks to now have an edge in two other tumor types.
You may also be interested in...
Affini-T Raises $175m For Bicoastal TCR Play Focused On KRAS-Mutated Solid Tumors
With Vida Ventures and Leaps by Bayer leading the round, Affini-T raises $175m to advance its KRAS-targeted T-cell therapies into the clinic and add technological capabilities.
Amgen’s Lumakras Falls Short Of Mirati’s Adagrasib In Pancreatic Cancer
The firm’s first-in-class KRAS inhibitor has shown lower objective response rates than Mirati’s rival candidate in a Phase I/II pancreatic cancer study, but experts note that its lung cancer opportunity, where Amgen can build up a considerable lead, is larger.
Ex-Novartis John Tsai Takes The Reins At Cardiovascular-Focused Forcefield Therapeutics
The ex-chief medical officer at Novartis is now CEO at the UK-based biotech, which he he told Scrip could have a ‘transformational’ therapy to protect patients after a heart attack.